Rib-X Pharmaceuticals Raises $20 Million to Advance its Industry-Leading Antibiotics Pipeline
Rib-X Pharmaceuticals, Inc. today announced that the Company has raised $20 million to support ongoing development of the Company’s industry-leading broad spectrum antibiotics pipeline, including late-stage clinical development of delafloxacin, which is expected to enter a Phase 2b study in early 2011.
"2011 will be a transformational year for Rib-X and these funds will directly support a number of key initiatives for the Company," said Mark Leuchtenberger, President and Chief Executive Officer at Rib-X. "In early 2011, we will begin a Phase 2b delafloxacin study to validate new objective endpoints for a near-term Phase 3 study and will initiate a long-term preclinical safety study with radezolid to demonstrate its key points of differentiation. We also expect to nominate an initial development candidate with activity against multi-drug resistant Gram-negative bacteria from our RX-04 program in early 2011. We are grateful for the confidence and continued strong financial support of our investors and look forward to being able to deliver on the clinical promise of our pipeline."
The financing was led by current investor Warburg Pincus LLC. "We are pleased to continue to support the Rib-X management team and the Company’s innovative antibiotic pipeline, which targets infections resistant to existing antibiotics," said Jonathan Leff, Managing Director at Warburg Pincus. "Through its deep expertise in antibiotics and insights in structure-based drug design around the bacterial ribosome, Rib-X has brought two differentiated products into advanced clinical development and has created a novel antibiotic discovery platform with the capability to target even the most resistant Gram-negative infections."
The Company’s pipeline includes:
Delafloxacin, an empiric first line, hospital focused novel fluoroquinolone antibiotic that offers both IV and oral versatility in the treatment of resistant infections;
Radezolid, a next generation oxazolidinone antibiotic designed to be safer, have a broader spectrum of coverage and increased activity against Gram-positive organisms as compared to other oxazolidinones; and
RX-04, the broadest-spectrum novel class of antibiotics active against serious, rapidly emerging multi-drug resistant bacteria, including Gram-negative bacteria.
About Rib-X Pharmaceuticals, Inc.
Rib-X Pharmaceuticals is developing broad spectrum antibiotics with superior coverage, safety and convenience to deliver new standards of care for patients with serious infections. The Company’s Nobel Prize winning platform enables a unique understanding of how antibiotics combat infection and has generated an industry leading pipeline spanning all phases of research and clinical development. http://www.rib-x.com.
MassBio Membership gives you:
Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members.
Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.
MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.
Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.
Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.
Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!
Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.